Related Posts
- High response rate with extended dosing of cemiplimab in advanced cutaneous squamous cell carcinoma
Background Cemiplimab (Libtayo®), a human monoclonal immunoglobulin G4 antibody to the programmed cell death-1 receptor,…
- High response rate with extended dosing of cemiplimab in advanced cutaneous squamous cell carcinoma
Background Cemiplimab (Libtayo®), a human monoclonal immunoglobulin G4 antibody to the programmed cell death-1 receptor,…
- Teclistamab Dosing and Response Sustainability in RRMM
KEY TAKEAWAYS The MajesTEC-1 phase I and II trials aimed to evaluate biweekly dosing of…